OT 202
Alternative Names: OT-202Latest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator Ocumension Therapeutics
- Class Eye disorder therapies; Pyrazoles
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry eyes
Most Recent Events
- 21 Mar 2024 Phase-II clinical trials in Dry eyes in China (Ophthalmic), prior to March 2024
- 21 Mar 2024 Ocumension Therapeutics completes enrolment in the phase II trial in Dry eyes in China (Ophthalmic)
- 16 Mar 2021 Ocumension Therapeutics intends to submit IND application to the NMPA in Dry eyes in first half of 2021 (Ocumension Therapeutics pipeline, March 2021)